CD8A and neoplasm: In a preclinical study, anti-PD1–IL-2v immunocytokine was proved to have superior ability to expand tumor-specific CD8+ effector-like T cells and therapeutic efficacy than the (agonistic) IL-2Rβγ-biased mutant IL-2 variant IL-2v in tandem with an anti-FAP scFv.379 These findings support the clinical development of RG6279, a bispecific anti-PD1–IL-2v fusion protein directing IL-2v to PD-1+ tumor-reactive T cells.